Darunavir population pharmacokinetic model based on HIV outpatient data
| Autor: | Johannes H. Proost, Cristina Gervasoni, Dario Cattaneo, Jan-Willem C. Alffenaar, Chiara Resnati, Quynh T D Tran, Tjip S. van der Werf, Wouter F W Bierman, Alper Daskapan, Jos G. W. Kosterink, Daniel J. Touw, Ymkje Stienstra |
|---|---|
| Přispěvatelé: | Microbes in Health and Disease (MHD), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Targeted Gynaecologic Oncology (TARGON), PharmacoTherapy, -Epidemiology and -Economics, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Nanomedicine & Drug Targeting, Groningen Research Institute for Asthma and COPD (GRIAC), Medicinal Chemistry and Bioanalysis (MCB) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty therapeutic drug monitoring Population Human immunodeficiency virus (HIV) HIV Infections HIV-1 infection medicine.disease_cause 030226 pharmacology & pharmacy protease inhibitor 03 medical and health sciences Young Adult 0302 clinical medicine Pharmacokinetics Internal medicine Outpatients medicine Humans Pharmacology (medical) University medical education Darunavir Aged Netherlands Pharmacology education.field_of_study medicine.diagnostic_test business.industry Limits of agreement Bayes Theorem HIV Protease Inhibitors Middle Aged University hospital Italy Therapeutic drug monitoring ComputingMethodologies_DOCUMENTANDTEXTPROCESSING HIV-1 Female Original Article business pharmacokinetics medicine.drug |
| Zdroj: | Therapeutic Drug Monitoring, 41(1), 59-65. LIPPINCOTT WILLIAMS & WILKINS Therapeutic Drug Monitoring |
| ISSN: | 0163-4356 |
| Popis: | Supplemental Digital Content is Available in the Text. Background: Darunavir is a second-generation protease inhibitor and is registered for the treatment of HIV-1 infection. The aim of this study was to develop and validate a darunavir population pharmacokinetic model based on data from daily practice. Methods: Data sets were obtained from 2 hospitals: ASST Fatebenefratelli Sacco University Hospital, Italy (hospital A), and University Medical Center Groningen, the Netherlands (hospital B). A pharmacokinetic model was developed using data from the largest data set using the iterative two-stage Bayesian procedure within the MWPharm software package. External validation was conducted using data from the smaller data set with Passing–Bablok regression and Bland–Altman analyses. Results: In total, data from 198 patients from hospital A and 170 patients from hospital B were eligible for inclusion. A 1-compartment model with first-order absorption and elimination resulted in the best model. The Passing–Bablok analysis demonstrated a linear correlation between measured concentration and predicted concentration with r2 = 0.97 (P < 0.05). The predicted values correlated well with the measured values as determined by a Bland–Altman analysis and were overestimated by a mean value of 0.12 mg/L (range 0.23–0.94 mg/L). A total of 98.2% of the predicted values were within the limits of agreement. Conclusions: A robust population pharmacokinetic model was developed, which can support therapeutic drug monitoring of darunavir in daily outpatient settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|